These patients are currently treated with highly toxic, intensive therapy.12, 14 Therefore, the addition of MEK inhibitors into the treatment regimen of iAMP21-ALL patients with RAS pathway mutations in the major clone may enable modification of chemotherapy intensity. Here, MAP2K7 is linked to acute lymphoblastic leukemia.